Here’s what’s in store for you in today’s issue:
🍄 Results from a global microdosing study
🍄 Ayahuasca vs. placebo
🍄 3D-printed psychedelics
🍄 Can mushrooms fight covid?
🍄 And more.
In this episode of the Daily Mushroom Podcast, we have Peg Peters. Peg is setting up a ketamine-assisted psychotherapy clinic just outside of Vancouver, BC. He discovered psychedelics in his mid 40s, taking a 6g dose of psilocybin mushrooms while accompanied by a therapist. After that experience his career in psychedelics took off!
An ayahuasca retreat could make you more empathetic!
In a recent study, participants reported reduced stress, anxiety, and depression after attending an ayahuasca ceremony… even those who were given a placebo.
However, only the ayahuasca users showed increased empathy.
The supportive group atmosphere could explain why people experienced benefits even without taking ayahuasca.
Researchers discovered that DOI (a psychedelic that’s similar to LSD and mescaline) can reduce anxiety and increase neural plasticity. Rats stopped showing anxious behaviours in response to fear triggers after a single dose!
A survey of ~900 psychedelic ceremony attendees revealed that psychedelic use is associated with a decreased belief in materialism, an increase in transcendentalism, and improved mental health. Participants showed more moderate views on metaphysical beliefs after the ceremony rather than extreme stances.
You could win $4,000+ in prizes for supporting legal access to psychedelics!
By becoming a member of the Canadian Psychedelic Association, you can help bring new regulations forward so Canadians in need can receive lifesaving psilocybin treatments.
If that’s not enough, you’ll also be entered to win an incredible prize package including:
Plus, your membership unlocks tons of other benefits such as conference discounts, exclusive interviews, resources, and media content.
Purchase a membership before December 10th to be entered in the giveaway!
This month’s issue of Los Angeles Magazine features an in-depth cover story on the city’s recent obsession with psychedelics.
Now, the story is being developed into a drama/comedy series called Psychedelic City (think Silicon Valley meets Limitless).
The writer hopes the show will “wipe away some of the stigmas that have been attached to psychedelics.”
The developers are also creating a Psychedelic City metaverse platform with immersive art, music, and experimental therapies.
Pasithea Therapeutics (KTTA) began offering an esketamine nasal spray at its UK clinics. It’s one of just three clinics in the UK that have been approved to provide the treatment.
MYND Life Sciences (MYND) began research on its biomarker test that aids in diagnosing multiple sclerosis. There are currently no physical indicators or lab tests that can diagnose the condition.
In an upcoming clinical trial, agarikon and turkey tail mushrooms will be given to covid-positive patients with mild symptoms. Researchers hope that the mushrooms’ antiviral and immune-boosting properties will prevent symptoms from worsening.
In a separate trial, the same blend of mushrooms will be given to subjects while getting vaccinated to see if it can boost antibody levels.
Nov 22 – Emyria Ltd (EMD) receives $5 million from one of Australia’s largest private investment groups Read more…
Nov 23 – Cybin (CYBN) Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities Read more…
Nov 23 – COMPASS Pathways (CMPS) granted fifth US patent for crystalline psilocybin Read more…
Nov 24 – Seelos Therapeutics (SEEL) Acquires Exclusive License of iX Biopharma’s Proprietary Wafer-Based Ketamine Delivery Platform Read more…
Nov 24 – NeonMind (NEON) Announces Successful Completion Of Pre-IND Consultation With FDA On Clinical Path For Obesity Drug Candidate NEO-001 Read more…
Nov 26 – Numinus (NUMI) Receives Conditional Approval to Graduate to the Toronto Stock Exchange Read more…
